Trade C4 Therapeutics, Inc. - CCCC CFD
What is C4 Therapeutics, Inc. (CCCC)?
C4 Therapeutics, Inc. is a biotechnology company focused on the discovery and development of novel therapies that harness targeted protein degradation. The company employs its proprietary platform to design small molecules capable of selectively degrading disease-causing proteins, aiming to address a range of therapeutic areas including oncology and other serious diseases. By leveraging the cell's natural protein disposal system, C4 Therapeutics seeks to expand the scope of druggable targets beyond traditional inhibition methods. The company's research and development efforts are centered on advancing its pipeline of degrader molecules through preclinical and clinical stages. Its approach represents a growing field within drug discovery that emphasizes the modulation of protein levels rather than activity alone. C4 Therapeutics operates within the broader biopharmaceutical industry, collaborating with academic institutions and other organizations to enhance its scientific capabilities. The company is headquartered in the United States and contributes to the evolving landscape of targeted therapies.
C4 Therapeutics, Inc. Stock Price Today: Live Overview
The price today is shaped by current trading levels for C4 Therapeutics, Inc., standing at $2.58. The intraday price fluctuated between $2.36 and $2.63 with a daily change of +10.7296%.
FAQ: C4 Therapeutics, Inc. (CCCC)
What is the current price of CCCC stock?
The current price is $2.58.
Does CCCC pay dividends?
C4 Therapeutics, Inc. does not pay dividends.
Does CCCC have a formal corporate presence or regional headquarters in the UAE?
C4 Therapeutics, Inc. operates in the UAE through partners and distributors without an official office or subsidiary.
What is CCCC best known for?
C4 Therapeutics, Inc. is most famous for its targeted protein degradation drug discovery platform.
What assets are typically shown together with CCCC?
Commonly shown alongside CCCC: Celestica Inc., Text SA, Tanger Inc
Latest shares articles



